CoverageForm 410-K10-Q8-K13D13G13F

SNGX Soligenix, Inc. - 8-K

Filed May 28, 2026. See issuer overview · financials · original on SEC.gov ↗
Accession
0001104659-26-067649
8.019.01

Item 8.01 - Other Events

126 words

Item 8.01 Other Events.

On May 28, 2026, Soligenix, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement dated January 23, 2026 (the “Sales Agreement”) with Rodman & Renshaw LLC, by an additional aggregate amount of $2,956,000. The Company previously sold approximately $3,445,000 of shares of common stock pursuant to the Sales Agreement under a prior prospectus supplement. A copy of the legal opinion as to the legality of the $2,956,000 of shares of common stock issuable under the Sales Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto.

​

Item 9.01 - Financial Statements and Exhibits

53 words

Item 9.01. Financial Statements and Exhibits.

​

(d)     Exhibits.

Exhibit No.

​ ​ ​

Description

5.1

​

Opinion of Duane Morris LLP

23.1

​

Consent of Duane Morris LLP

104

​

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

​

​

​

​

​

​

2

​